Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Pimicotinib with Itraconazole or Rifampicin in Healthy Volunteers
NCT06089733Phase 1Completed
- Sponsor
- Abbisko Therapeutics
- Start
- Apr 2023
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of pimicotinib in tenosynovial giant cell tumor (TGCT) (2 arms), sponsored by Abbisko Therapeutics. Primary endpoints: Peak Plasma Concentration at 1 month and Area Under the Curve at 1 month. Started Apr 2023; status: completed.
02
Drugs
pimicotinib
03
Conditions
tenosynovial giant cell tumor (TGCT)
Beyond the preview
Go deeper on NCT06089733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06089733.